您目前的位置:院首页>首页 > Professor

Cui Jingrong

Cui Jingrong

 

Jing-rong Cui, Born in April. 26, 1952, in Beijing, China; 1973.9-1976.12: School of Basic Medical Sciences, Beijing Medical College (Peking University Health Science Center);  1977 – Present:  to a post of Teaching  Assistant Lecturer Associate Professor and Professor at Department of  PharmacologySchool of Pharmaceutical Sciences, Peking University Health Science Center; 1992-1993: engaged in research on the  Molecular Pharmacology and Molecular Toxicology at free University, the Holland; At present: to appoint director of Pharmacology  group of National research Laboratory of Natural and Biomimetic Drugs and  head of Department of Molecular and Cellular Pharmacology. Committee member of Association of China Anticancer and Anticancer Drugs.Undertook research item for 10 topic such as: the 8th 9th and 10th “Five economic development plan” ”973” item of nationalnature science fund of national …… . Significant Published research papers for more 90 piece, which there are 45 SCI papers and had apply  patents of China America and world for 10 item.

Research Interests:

At present, the main research antitumor drugs in screeningpharmacodynamicsaction mechanisms The national screening laboratory will follow research development in mechanisms of tumor occur, and to establishing new method and model, such as: Key enzyme of Signal transductioninduce cell apoptosis and differentiationoncogene and tumor suppressor genemicrotubule proteinanti-tumor metastasiscancer protectionet al, and to screening for discovering lead compounds and new drugs.

 Selected Publications:

1. Cui jingrong, Hui Yu,Xiang You-qing and Zhang Lihe. Effect of  8-Chloroadenosine on undifferetiatied HL-60 cell line.Journal of Chinese Phamaceutical Sciences 2003,12(4):215-221.

2.  S.-Y. Wei, M. Li, S. A. Tang, W. Sun, B. Xu, J.- R. Cui*, W.- H. Lin, Induction of apoptosis accompanying with G1 phase arrest and microtubule disassembly in human hepatoma cells by jaspolide B, a new isomalabaricane-type triterpene, Cancer Lett., 2008, 262: 114-122.

3. C. Tang, Zh.-L. Zhang, B. Xu, M. Li, J.-Y. Liu, J.-R.Cui* Two newly synthesized 5-methyltetrahydrofolate-like compounds inhibit methionine synthase activity accompanied by cell cycle arrest in G1/S phase and apoptosis in vitro. Anti-cancer Drugs 2008, 19: 697-704

4.  L.-P. Pang, W. Huang, Q. Sunc, W. Guoa, R.-T. Li, J.-R. Cui*, SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells, Anti-Cancer Drugs, 2008, 19: 167-174.

5.  N. Zhang, G. Wei, L. Wang, W. Wang, B. Xu, Z.-M.Ge, M. Li, R. Tao, J.-R. Cui*, Effect of TM208 on QGY-7703 xenograft tumor growth, Anti-Cancer Drugs, 2008, 19(6):593-598.

6.       M. Li, S.-Y. Wei, B. Xu, W. Guo, D.-L. Liu, J.-R. Cui*, X. Sheng, YAOPro-apoptotic and microtubule-disassembly effects of ardisiacrispin (A+B) from Ardisia crenata on human hepatoma Bel-7402 cells, J. Asian Nat. Prod. Res., 2008, 19 (7): 256-262.

7.  X.-H. Wang, B. Xu, J.–T.  Liu, J.-R. Cui*, Effect of β-escin sodium on endothelial cells proliferation,migration and apoptosis. Vascular Pharmacology , 2008, 49:158-165.

8.       H.-Y. Yang, W. Guo, B. Xu, M. Li, J.-R. Cui, Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma, Anti-Cancer Drugs ,2007, 18:1133-1137.

9.       Y.-X. Ma, H.-Z. Fu, M. Li, W. Sun, B. Xu, J.-R. Cui*, An anticancer effect of a new saponin component from Gymnocladus chinensis Baillon through inactivation of NF-KB, Anticancer Drugs, 2007 18. (1): 41-46.

10.  Q. Sun, R.-T. Li, W. Guo, J.-R. Cui*, Tie-Ming Cheng and Ze Mei Ge, Novel call of cyclophosphaminde Prodrug:cyclophosphamide spiropiperaziniums(CPSP), Bioorganic Medicinal Chemistry Letters, 2006,16:3727-3730.